EXHIBIT 12.1
OncoGenex Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
| Nine
Months Ended September 30, 2011 |
||||||||||||||||||||||||
| Fiscal Year Ended, December 31, | ||||||||||||||||||||||||
| (In $000’s, except ratio) |
2006 | 2007 | 2008 | 2009 | 2010 | |||||||||||||||||||
| Fixed Charges: |
||||||||||||||||||||||||
| Interest expense |
$ | — | $ | 193 | $ | 749 | $ | 1,251 | $ | 1,172 | $ | 825 | ||||||||||||
| Amortized premiums discounts and captialized expenses related to indebtedness |
2,604 | 2,944 | 1,973 | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | 2,604 | $ | 3,137 | $ | 2,722 | $ | 1,251 | $ | 1,172 | $ | 825 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Earnings (loss): |
||||||||||||||||||||||||
| Net income (loss) before tax benefit (provision) |
$ | (10,919 | ) | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (5,104 | ) | ||||||
| Add fixed charges |
2,604 | 3,137 | 2,722 | 1,251 | 1,172 | 825 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | (8,315 | ) | $ | (4,686 | ) | $ | 7,969 | $ | (1,214 | ) | $ | (14,412 | ) | $ | (4,279 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Ratio of earnings to fixed charges |
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Deficiency of earnings to fixed charges |
$ | (10,919 | ) | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (5,104 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||